Targeted Drug Delivery Strategies in Bone Cancer

Targeted drug delivery in bone cancer seeks to concentrate therapeutic agents within malignant bone tissue while minimising systemic exposure. The unique mineralised matrix and dense vasculature of bone pose barriers to conventional chemotherapy, driving the development of specialised carriers that exploit bone-binding ligands, pH gradients and cellular receptors. Bisphosphonate derivatives such as alendronate confer affinity for hydroxyapatite, directing nanocarriers to sites of bone remodelling. Ligand-modified nanoparticles and micelles bearing osteotropic moieties or tumour-specific antibodies achieve selective uptake by osteosarcoma cells or bone-metastatic lesions. Strategies combine passive accumulation via the enhanced permeability and retention effect with active targeting through receptor-mediated endocytosis. Stimuli-responsive systems, including pH-sensitive liposomes and redox-responsive nanogels, trigger drug release in the acidic or reductive tumour microenvironment. Biomimetic platforms harness cell membranes or extracellular matrix components to disguise payloads and prolong circulation, enabling multi-modal approaches that integrate chemotherapeutics, gene silencers and imaging agents. Together, these innovations address drug resistance, reduce off-target toxicity and open avenues for personalised interventions against both primary bone tumours and skeletal metastases.

Research from Nature Portfolio

Self-assembled micelles combining doxorubicin with polyethylene glycol and alendronate illustrate how amphiphilic conjugates exploit bone affinity and pH-triggered release. These micelles remain stable in circulation, preferentially accumulate on hydroxyapatite surfaces and discharge cytotoxic payloads in the acidic tumour milieu, resulting in delayed tumour growth and reduced cardiotoxicity in bone-metastasis models. In a complementary approach, polymeric nanomedicines coated with an alendronic acid corona form a stealth layer that binds bone mineral and shields core polymers. The resulting nanoparticles demonstrate selective uptake by osteosarcoma cells over non-target tissues, sustained serum stability and efficient delivery of doxorubicin to bone microenvironments, underscoring the potential of bisphosphonate-driven targeting to enhance therapeutic indices in bone malignancies.

Targeted Drug Delivery Strategies in Bone Cancer publication trend

The graph below shows the total number of articles in targeted drug delivery strategies in bone cancer across all publications each year (not limited to Nature Index journals).

Technical terms

Nanocarrier: A nanoscale vehicle designed to transport therapeutic agents to specific tissues or cells.

Bisphosphonate (e.g., alendronate): A bone-seeking ligand that binds hydroxyapatite, used to target drug delivery to mineralised bone.

Hydroxyapatite: The primary mineral component of bone, serving as a binding substrate for osteotropic agents.

Osteosarcoma: A primary malignant bone tumour arising from osteoblast lineage cells.

Passive targeting: Accumulation of nanocarriers in tumour tissue via enhanced permeability and retention.

Active targeting: Specific binding of surface-modified carriers to cellular receptors or bone-binding sites.

pH-sensitive release: Stimuli-responsive drug discharge triggered by the acidic tumour microenvironment.

References

1. Current advance of nanotechnology in diagnosis and treatment for malignant tumors. Signal Transduction and Targeted Therapy (2024).
2. Dynamic regulation of drug biodistribution by turning tumors into decoys for biomimetic nanoplatform to enhance the chemotherapeutic efficacy of breast cancer with bone metastasis. Exploration (2023).
3. Active targeting schemes for nano-drug delivery systems in osteosarcoma therapeutics. Journal of Nanobiotechnology (2023).
4. Doxorubicin-poly (ethylene glycol)-alendronate self-assembled micelles for targeted therapy of bone metastatic cancer. Scientific Reports (2015).
5. Engineered Nanomedicine with Alendronic Acid Corona Improves Targeting to Osteosarcoma. Scientific Reports (2016).